De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
TransMedics Group Beheer
Beheer criteriumcontroles 4/4
De CEO TransMedics Group's is Waleed Hassanein, benoemd in Aug1998, heeft een ambtstermijn van 26.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.76M, bestaande uit 9.4% salaris en 90.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.41% van de aandelen van het bedrijf, ter waarde $ 73.69M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.5 jaar en 11.2 jaar.
Belangrijke informatie
Waleed Hassanein
Algemeen directeur
US$6.8m
Totale compensatie
| Percentage CEO-salaris | 9.4% |
| Dienstverband CEO | 26.2yrs |
| Eigendom CEO | 1.4% |
| Management gemiddelde ambtstermijn | 7.5yrs |
| Gemiddelde ambtstermijn bestuur | 11.2yrs |
Recente managementupdates
Recent updates
Returns Are Gaining Momentum At TransMedics Group (NASDAQ:TMDX)
Sep 18
TransMedics: Take Profits While The Valuation Is Sky High
Sep 18TransMedics: Wide Moat Player At A Lower Valuation Than Peers
Sep 10TransMedics Group, Inc.'s (NASDAQ:TMDX) P/S Is Still On The Mark Following 25% Share Price Bounce
Aug 28TransMedics: Heart And Lungs Will Drive The Next Leg Higher
Aug 19Analysts Just Made A Meaningful Upgrade To Their TransMedics Group, Inc. (NASDAQ:TMDX) Forecasts
Aug 06TransMedics Group: Providing Long-Term Detailed Forecast And Upgrading To Buy
Aug 04TransMedics Group, Inc. Just Recorded A 66% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 02TransMedics Group Stock: Too Far, Too Fast
Jul 08TransMedics: NOP, Logistics And Transport Are Key Growth Drivers But Stock Is Pricey
Jun 17TransMedics Group (NASDAQ:TMDX) Might Have The Makings Of A Multi-Bagger
Jun 10TransMedics: Transportation Supporting Growth
May 21TransMedics Group: Looking At The Road Ahead After An Exceptional Q1 (Rating Downgrade)
May 06TransMedics Group, Inc. (NASDAQ:TMDX) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Apr 24TransMedics Group: Founder Led Company With Solid Potential
Apr 19Is TransMedics Group (NASDAQ:TMDX) Using Too Much Debt?
Apr 11TransMedics Group: Emerging Medical Device Market Leader With A Long Growth Runway
Mar 19TransMedics Group: Huge Opportunity In Organ Transplants
Mar 12TransMedics: A Very Expensive Growth Stock
Feb 07With TransMedics Group, Inc. (NASDAQ:TMDX) It Looks Like You'll Get What You Pay For
Jan 23Calculating The Fair Value Of TransMedics Group, Inc. (NASDAQ:TMDX)
Jan 02Does TransMedics Group (NASDAQ:TMDX) Have A Healthy Balance Sheet?
Nov 05This Just In: Analysts Are Boosting Their TransMedics Group, Inc. (NASDAQ:TMDX) Outlook for This Year
Aug 06TransMedics Group (NASDAQ:TMDX) Has Debt But No Earnings; Should You Worry?
Aug 02TransMedics Group, Inc. (NASDAQ:TMDX) Not Lagging Industry On Growth Or Pricing
Jun 29Brokers Are Upgrading Their Views On TransMedics Group, Inc. (NASDAQ:TMDX) With These New Forecasts
May 06Is TransMedics Group (NASDAQ:TMDX) Using Too Much Debt?
Apr 27Estimating The Intrinsic Value Of TransMedics Group, Inc. (NASDAQ:TMDX)
Apr 09Is TransMedics Group (NASDAQ:TMDX) A Risky Investment?
Jan 16Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$3m |
| Mar 31 2024 | n/a | n/a | -US$10m |
| Dec 31 2023 | US$7m | US$634k | -US$25m |
| Sep 30 2023 | n/a | n/a | -US$36m |
| Jun 30 2023 | n/a | n/a | -US$18m |
| Mar 31 2023 | n/a | n/a | -US$28m |
| Dec 31 2022 | US$3m | US$575k | -US$36m |
| Sep 30 2022 | n/a | n/a | -US$42m |
| Jun 30 2022 | n/a | n/a | -US$48m |
| Mar 31 2022 | n/a | n/a | -US$47m |
| Dec 31 2021 | US$7m | US$535k | -US$44m |
| Sep 30 2021 | n/a | n/a | -US$38m |
| Jun 30 2021 | n/a | n/a | -US$30m |
| Mar 31 2021 | n/a | n/a | -US$28m |
| Dec 31 2020 | US$2m | US$534k | -US$29m |
| Sep 30 2020 | n/a | n/a | -US$32m |
| Jun 30 2020 | n/a | n/a | -US$35m |
| Mar 31 2020 | n/a | n/a | -US$36m |
| Dec 28 2019 | US$3m | US$449k | -US$34m |
| Sep 28 2019 | n/a | n/a | -US$32m |
| Jun 29 2019 | n/a | n/a | -US$29m |
| Mar 30 2019 | n/a | n/a | -US$26m |
| Dec 29 2018 | US$524k | US$384k | -US$24m |
| Sep 29 2018 | n/a | n/a | -US$21m |
| Jun 30 2018 | n/a | n/a | -US$20m |
| Mar 31 2018 | n/a | n/a | -US$20m |
| Dec 30 2017 | US$601k | US$351k | -US$21m |
Compensatie versus markt: De totale vergoeding ($USD 6.76M ) Waleed } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 8.11M ).
Compensatie versus inkomsten: De vergoeding van Waleed is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Waleed Hassanein (56 yo)
26.2yrs
Tenure
US$6,758,070
Compensatie
Dr. Waleed H. Hassanein, M.D. is the Founder of Transmedics Group, Inc. and has been its President, Chief Executive Officer and Director since August 1998. He Founded TransMedics, Inc. in August 1998 and h...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 26.2yrs | US$6.76m | 1.41% $ 65.2m | |
| CFO, Treasurer & Secretary | 9.6yrs | US$2.64m | 0.064% $ 3.0m | |
| Senior Vice President of Supply Chain & Operations | 1.8yrs | US$2.52m | 0.0097% $ 447.8k | |
| Senior VP | 1.3yrs | US$2.35m | 0.027% $ 1.2m | |
| Chief Commercial Officer | 18.8yrs | US$2.63m | 0.062% $ 2.9m | |
| Vice President of Global Regulatory Affairs | 5.3yrs | US$813.47k | geen gegevens |
7.5yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van TMDX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 26.2yrs | US$6.76m | 1.41% $ 65.2m | |
| Independent Director | 21.8yrs | US$220.28k | 0.91% $ 42.3m | |
| Independent Director | 3.8yrs | US$238.62k | 0.0036% $ 166.0k | |
| Independent Chairman | 13.8yrs | US$262.32k | 0.52% $ 24.2m | |
| Member of Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 8.7yrs | US$232.26k | 0.0022% $ 101.5k | |
| Independent Director | 8.2yrs | US$237.74k | 0.0036% $ 166.0k |
11.2yrs
Gemiddelde duur
70.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van TMDX zijn ervaren en ervaren (gemiddelde ambtstermijn van 11.2 jaar).